Anginera technology was derived from the FDA-approved wound management product marketed as Dermagraft™. Both products use a qualified bank of human fibroblast cells that are cultured on a three-dimensional bioabsorbable scaffold material to create a viable tissue. Dermagraft has been clinically proven to be safe and effective, and has been used to treat over 30,000 patients for diabetic foot ulcers.View Dermagraft background
When applied as an epicardial patch to an ischemic area of the heart, the living tissue provides cytokines and growth factors needed to induce angiogenesis and tissue repair.
Preclinical studies provide evidence that Anginera supports improved cardiac function in a chronic ischemic heart model. A major benefit of Anginera treatment may be the improvement of blood flow to areas of the heart that are not treatable by conventional revascularization therapies (e.g., CABG and stents).